TriSalus Life Sciences Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TriSalus Life Sciences reports record revenue growth and expands clinical trials

TriSalus Life Sciences demonstrated strong financial performance and operational efficiency in Q2 2024, driven by significant revenue growth and high gross margins.
The company's strategic focus on clinical trials, innovative treatment approaches, and financial flexibility positions it well for future growth and market expansion.
While facing challenges in executing combination therapies and maintaining growth momentum, TriSalus has opportunities to enhance treatment outcomes, diversify its portfolio, and strengthen its market position.

TriSalus Life Sciences reports robust Q3 earnings and strategic growth plans

TriSalus Life Sciences demonstrated strong financial performance in Q3, with significant revenue growth and a focus on cost management.
The company's strategic partnerships and upcoming product launches position it well for market expansion and innovation.
While challenges like expense reduction and achieving profitability exist, TriSalus has opportunities for growth through new product launches and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Results Full financial results fo.

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) and the United States Adopted Names (USAN) Council have approved the use of the nonproprietary name of "nelitolimod" for SD-101, a class C TLR-9 agonist. Ne.

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the publication in Current Medical Research and Opinion a manuscript detailing a real-world study of the use of the pressure-enabled drug delivery (PEDD™) method with the TriNav® device for trans-arterial chemoembolization (TACE) and trans-arterial radioemboliza.

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

TriSalus Life Sciences is a biotech focused on developing novel therapies for cancer, particularly liver cancer. They have a unique drug delivery system called TriNav that overcomes barriers imposed by tumor anatomy to improve treatment effectiveness. Their pipeline consists of a single immunotherapeutic agent called SD-101, which is being assessed in phase 1 trials for various types of liver-and pancreas-associated cancer.

TriSalus Life Sciences: Rocket-Like Recovery Could Be An Inflection Point

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announce today that the Centers for Medicare & Medicaid Services (CMS) has created a New Technology Healthcare Common Procedure Coding System (HCPCS) code for procedures involving the TriNav® Infusion System. This new code, HCPCS C9797, has been assigned to t.

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update. “Today marks an important milestone for TriSalus as we host our first quarterly earnings call as a public company. I am proud of our team's consi.

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will host a conference call and webcast on November 14, 2023, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2023, and provide a business update. A press release detailing third quarter results will be issued prior to.

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

DENVER & SAN DIEGO--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting. The PERIO-01 Phase 1 study for uveal melanoma with liver metastases (UMLM), studied SD-101 deli.

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

DENVER & SAN DIEGO--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced initial positive safety and feasibility data from a Phase 1 trial at the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting. TriSalus is studying an investigational class C toll-like receptor-9 (TLR9) agonist, SD-101, delivered intravasc.

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023, in San Diego, California. Presentation details for SITC 2023 are as foll.

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

News for TriSalus Life Sciences Inc Stock (TLSI)